论文部分内容阅读
美国华盛顿消息:欧洲的几项试验表明,急性心肌梗塞时静脉推注速效血栓溶解剂(APSAC)可与链激酶输注相匹敌。美国多中心试验的初步结果也证明此实验性药物是有希望的。由于茴香酰化-血纤维蛋白溶酶原-链激酶激活剂复合物(anisoylated-plasminogen-streptokinase activator complex,APSAC)具有再输注率高、再闭塞率低、释放快及应用方便等优点,在世界心脏病学会会议上受到好评。在3～5分钟内注射APSAC,其半寿期为90分钟。而链激酶输注需一小时,其半寿期为
Washington, United States: Several trials in Europe have shown that intravenous bolus APTAC can rival streptokinase infusion in acute myocardial infarction. The preliminary results of the U.S. multicentre trial also demonstrate that this experimental drug is promising. The anisoylated-plasminogen-streptokinase activator complex (APSAC) has the advantages of high reperfusion rate, low reocclusion rate, quick release and easy application. The World Society of Cardiology was acclaimed. APSAC is injected within 3 to 5 minutes with a half-life of 90 minutes. Streptokinase infusion takes one hour, its half-life is